参考文献/References:
[1] Olschewski H, Kovacs G. ESC guidelines 2015 on pulmonary hypertension[J]. Herz,2015,40(8):1055-1060.
[2] Buys R, Avila A, Cornelissen VA.Exercise training improves physical fitness in patients with pulmonary arterial hypertension:a systematic review and meta-analysis of controlled trials[J]. BMC Pulm Med,2015,15(1):40.
[3] Saglam M, Arikan H, Vardar-Yagli N, et al.Inspiratory muscle training in pulmonary arterial hypertension[J]. J Cardiopulm Rehabil Prev,2015,35(3):198-206.
[4] Awdish R, Small B, Cajigas H.Development of a modified yoga program for pulmonary hypertension:a case series[J]. Altern Ther Health Med,2015,21(2):48-52.
[5] Sitbon O, Humbert M, Jaïs X, et al.Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension[J]. Circulation,2005,111(23):3105-3111.
[6] Saito Y, Nakamura K, Akagi S, et al.Epoprostenol sodium for treatment of pulmonary arterial hypertension[J]. Vasc Health Risk Manag,2015,11:265-270.
[7] Volkov AV, Kurmukov IA, Iudkina NN, et al.Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis[J]. Ter Arkh,2015,87(1):49-56.
[8] Ploegstra MJ, Zijlstra WM, Douwes JM,et al.Prognostic factors in pediatric pulmonary arterial hypertension:a systematic review and meta-analysis [J]. Int J Cardiol,2015,184:198-207.
[9] Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension[J]. Am Heart J,2006, 151(4):851.e1-e5.
[10] Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines[J]. Chest,2007,131(6):1917-1928.
[11] Makowski CT, Rissmiller RW, Bullington WM.Riociguat:a novel new drug for treatment of pulmonary hypertension[J]. Pharmacotherapy,2015,35(5):502-519.
[12] Xiao JW, Zhu XY, Wang QG, et al.Acute effects of rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects[J]. Circ J,2015,79(6):1342-1348.
[13] Machuca T, de Perrot M.When to refer a patient with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy[J]. Can J Cardiol,2015,31(4):509-514.
[14] Edemskiǐ AG, Cherniavskiǐ AM, Cherniavskiǐ MA, et al. Five-year results of surgical management of patients with chronic post-embolic pulmonary hypertension [J]. Angiol Sosud Khir,2015,21(1):165-169.
[15] Nakamura M, Sunagawa O, Tsuchiya H, et al.Rescue balloon pulmonary angioplasty under veno-arterial extracorporeal membrane oxygenation in a patient with acute exacerbation of chronic thromboembolic pulmonary hypertension[J]. Int Heart J,2015,56(1):116-120.
[16] Chiu JS, Zuckerman WA, Turner ME, et al.Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes[J]. J Heart Lung Transplant,2015,34(3):376-380.
[17] Kim SH, Jang WS, Lim HG, et al.Potts shunt in patients with primary pulmonary hypertension[J]. Korean J Thorac Cardiovasc Surg,2015,48(1):52-54.
[18] McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension[J]. Turk Kardiyol Dern Ars,2014,42(Suppl 1):95-105.
[19] Gai XY, Wei YH, Zhang W, et al.Echinacoside induces rat pulmonary artery vasorelaxation by opening the NO-cGMP-PKG-BKCa channels and reducing intracellular Ca(2+)levels[J].Acta Pharmacol Sin,2015,36(5):587-596.
[20] Wang RX, He RL, Jiao HX, et al.Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats[J]. Cell Physiol Biochem,2015,35(4):1467-1481.
[21] Huang X, Zou L, Yu X, et al.Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway[J]. J Mol Cell Cardiol,2015,82:153-166.
[22] van der Laarse A, Cobbaert CM, Umar S.Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle(2013 Grover Conference Series)[J]. Pulm Circ,2015,5(1):73-80.
[23] Betkier-Lipińska K, Ryczek R, Cwetsch A. New directions in the therapy of pulmonary arterial hypertension[J]. Pol Merkur Lekarski,2014,37(222):321-323.
相似文献/References:
[1]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(3):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
[4]朱峰,陈铀.先天性心脏病相关肺动脉高压的治疗进展[J].心血管病学进展,2019,(6):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
ZHU Feng,CHEN You.Congenital Heart Disease-related Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
[5]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[6]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(3):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[7]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[8]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[9]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[10]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]